Live Talk Session 6: May 19, 2022 – Biotin’s effect on lab tests

May 23, 2022

Dr. Lewis Blevins talks with guest Dr. Saleh Aldasouqi, Professor, Chief, Division of Endocrinology and Metabolism, and Clinician at Michigan State University Specialty Center, Endocrinology Clinic, about Biotin use and its interference with laboratory tests. This is definitely something you need to know to plan discontinuance of the supplement to allow for lab testing. You won’t want to miss this discussion. To learn more about this issue you can access the links we included in the article related to this podcasts
with more details on the issues with Biotin use and how it can lead to misdiagnosis.

Live Talk: Session 5, May 12, 2022 – Advocacy, patient needs and support

May 13, 2022

Our live talk session from May 12 is now available on-demand with guests Jill Sisco, president of the Acromegaly Community, and Sharmyn McGraw from the Pacific Neuroscience Institute.  This was a fascinating perspective on the challenges and opportunities for patient advocacy programs with two of the leading patient advocates in the world of pituitary disease, specifically Cushing’s and acromegaly.  We talked about the voice of the patient initiatives, support groups, unmet needs, access to medication, and new initiatives to participate in making life better for people dealing with pituitary disease.  Don’t miss it, and join us next Thursday for another Live Talk session!

Live Talk: Session 3 from April 28, 2022, now on demand.

May 2, 2022

In session three, we cover the many possible complications from pituitary surgery in terms of pituitary function and the anatomy around the gland. This is a comprehensive review of potential consequences that all pituitary patients, whether they have had, or are about to have surgery, should know and discuss with their surgeons.

Recorlev®

February 18, 2022

In today’s podcast directed to physicians, PWN co-founder Dr. Lewis Blevins discusses the drug Recolev® (levoketoconazole) recently approved by the FDA to treat endogenous Cushing’s Syndrome.

Mifepristone (Korlym®)

December 9, 2021

In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.

Isturisa® (osilodrostat)

December 6, 2021

Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work.  In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.

Metyrapone

December 3, 2021

The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects. 

Coming up next, a discussion on the drug Isturiza® (osilodrostat).